Effect of Some Drugs on Liver Fibrosis

Phase 3

Recruiting

• Conditions: Liver Fibroses
• Interventions: Drug: Candesartan; Drug: Ramipril

• Registration Number: NCT03770936
• Lead Sponsor: Sherief Abd-Elsalam

Brief Summary

Effect of Some Drugs on Liver Fibrosis

Detailed Description

The study aimed at evaluating the effect of Some Drugs on Liver Fibrosis

Study Timeline

• Study Start: 2018-10-01
• Status Verified: 2018-12
• Study First Submitted: 2018-12-07
• Study First Submitted QC: 2018-12-07
• Last Update Submitted: 2018-12-07
• Study First Posted: 2018-12-10
• Last Update Posted: 2018-12-10
• Primary Completion: 2026-10
• Study Completion: 2027-11

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 45

Inclusion Criteria

• chronic hepatitis C

Exclusion Criteria

• Acute hepatitis
• Thalassemia

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Candesartan	Candesartan	Candesartan 8 mg/day
Ramipril	Ramipril	Ramipril 1.25 mg/day

Primary Outcome Measures

Name	Time	Method
Change in Fibroscan or APRI score	6 months	Change in Fibroscan or APRI score

Trial Locations

Locations (1)

Sherief Abd-Elsalam; 🇪🇬 Tanta, Egypt